Invezz
21 Jul 2026, 07:26 UTC · 5h ago
Novartis Q2 surpasses estimates despite 50% Entresto sales drop
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Invezz
21 Jul 2026, 07:26 UTC · 5h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Novartis expects a $4 billion annual sales decline due to generic competition for its top-selling drug Entresto. — A multi-billion dollar revenue loss from a flagship product creates a significant structural headwind for the company's top line.
-0.80Novartis reported Q2 core operating income of $5.94 billion, beating analyst expectations of approximately $5.31 billion. — Beating profit estimates demonstrates operational efficiency and cost management despite revenue pressures.
+0.40Management reaffirmed full-year guidance and expects low single-digit core operating income growth. — Maintaining guidance provides stability and suggests the company believes its growth targets are still achievable.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
Newer drugs including Kisqali, Scemblix, and Cosentyx are currently offsetting declines in established products. — Proof of a diversifying pipeline reduces the risk of over-reliance on a single drug like Entresto.
+0.20Which stocks this story touches
The company beat Q2 core operating profit estimates and reaffirmed full-year guidance, though it faces significant headwinds from Entresto sales declines.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Bloomberg Markets and Finance
35m ago
